Gene doping
From Wikipedia, the free encyclopedia
Gene doping is defined by the World Anti-Doping Agency as "the non-therapeutic use of cells, genes, genetic elements, or of the modulation of gene expression, having the capacity to improve athletic performance". [1] A complex ethical and philosophical issue is what defines "gene doping", especially in the context of bioethical debates about human enhancement.[1] An example of gene doping could involve the recreational use of gene therapies intended to treat muscle-wasting disorders. Many of these chemicals may be indistinguishable from their natural counterparts. In such cases, nothing unusual would enter the bloodstream so officials would detect nothing in a blood or urine test.
The historical development of policy associated with gene doping began in 2001 when the International Olympic Committee (IOC) Medical Commission met to discuss the implications of gene therapy for sport. It was shortly followed by the World Anti-Doping Agency (WADA), which met in 2002 to discuss genetic enhancement at Cold Spring Harbor Laboratory in New York. Also in 2002, the United States President’s Council on Bioethics met twice to discuss the ethics of genetic technology related to sport. In 2003, WADA decided to include a prohibition of gene doping within their World Anti-Doping Code, which is formalized in its 2004 World Anti-Doping Code. Further, the American Association for the Advancement of Science (AAAS) met in 2003 and 2004 to discuss the science and ethics of gene transfer technology for sport.
The World Anti-Doping Agency (WADA) has already asked scientists to help find ways to prevent gene therapy from becoming the newest means of doping. In December 2005, the World Anti-Doping Agency hosted its second landmark meeting on gene doping, which took place in Stockholm. At this meeting, the delegates drafted a declaration on gene doping which, for the first time, included a strong discouragement of the use of genetic testing for performance.
The first product to be associated with genetic doping emerged on the approach to the Turin 2006 Olympic Winter Games, where repoxygen was discussed as a possible substance in use at the Games.
[edit] See also
New description of genedoping on the prohibited list of the WADA: "The transfer of cells or genetic elements or the use of cells, genetic elements or pharmacological agents to modulating expression of endogenous genes having the capacity to enhance athletic performance, is prohibited”
[edit] References
- ^ Miah, Andy (2004). Genetically Modified Athletes: Biomedical Ethics, Gene Doping and Sport. Routledge. ISBN 0-415-29880-6.
[edit] External links
- Gene Doping Documentary from Michigan State University
- World Anti-Doping Agency Website
- Genetically Modified Athletes: Biomedical Ethics, Gene Doping and Sport (Routledge, 2004), by Andy Miah
- Bioethics & Sport Blog
- Scientific American July 2004 - Gene Doping
- Miah, A. (2003) Gene Doping: Sport, Values & Bioethics. In Glasa, J. (Ed.) The Ethics of Human Genetics. Strasburg, Council of Europe, pp.171-180
- Forum for the Analysis of Sport Technology
- Scientific American Magazine (July 2004 Issue) Gene Doping
- Summary of TAB Working report 124 "Gene Doping" on behalf of the German Parliament (April 2008) cf. also Findings (February 2008)
- The social aspects of Gene Doping is discussed in the RU Sirius Show #117 6.29.07 with Steve Wozniak and WorldChanger Jamais Cascio.
